Difference between revisions of "Increasing Willingness and/or Ability of Governments to Sponsor Biotech Research."
(Daniel2 moved to Legal Restrictions for Biotech increasing in certain countries, decreasing in others) |
|||
Line 1: | Line 1: | ||
==Description:== | |||
Many governments are willing to support and sponsor fundamental research in biotech by massive funds, many have declared biotech a core issue in their economic strategy and many are trying to attract biotech companies to move production sites and research activities to the territory of their countries. A biotech company is almost always welcome. <br> | |||
==Enablers:== | |||
• Biotech has been declared a core topic of the economic policy of many governments | |||
• Governments perceive biotech industry as one possible panacea to solve economic problems and to trigger economic growth | |||
• Lack of private venture capital in certain countries triggering calls for government sponsorship | |||
• Worldwide diseases | |||
• Desire to increase Standard of living by both, creation of high qualification jobs and availability of state of the art medicine | |||
• Few other alternatives for Research Sponsorship | |||
==Inhibitors:== | |||
• Budgetary limitations | |||
• Exploding healthcare costs | |||
• Priorities other than biotech | |||
• Other promising opportunities for investment and sponsorship | |||
==Paradigms:== | |||
• Perception of biotechnology as a core topic for the competitiveness of a nation | |||
==Experts:== | |||
• Ernst & Young, biotech Report | |||
==Timing:== | |||
• 2000 – 2005 Biotech strategies by several countries | |||
• 2001: Healthcare Spending by US Goverment passes 20% of governmental budget | |||
• 2001: Lisbon Agenda; Strategic vision of EU for Biotech in Europe | |||
• 11/2002: First People suffering from SARS identified in Province of Guangdong, China | |||
• 2005: 124 cases of bird flu reported, 63 persons death since 2003; 150 million animals killed for reasons of precaution | |||
==Web Resources:== | |||
• WHO |
Revision as of 12:31, 2 December 2005
Description:
Many governments are willing to support and sponsor fundamental research in biotech by massive funds, many have declared biotech a core issue in their economic strategy and many are trying to attract biotech companies to move production sites and research activities to the territory of their countries. A biotech company is almost always welcome.
Enablers:
• Biotech has been declared a core topic of the economic policy of many governments • Governments perceive biotech industry as one possible panacea to solve economic problems and to trigger economic growth • Lack of private venture capital in certain countries triggering calls for government sponsorship • Worldwide diseases • Desire to increase Standard of living by both, creation of high qualification jobs and availability of state of the art medicine • Few other alternatives for Research Sponsorship
Inhibitors:
• Budgetary limitations • Exploding healthcare costs • Priorities other than biotech • Other promising opportunities for investment and sponsorship
Paradigms:
• Perception of biotechnology as a core topic for the competitiveness of a nation
Experts:
• Ernst & Young, biotech Report
Timing:
• 2000 – 2005 Biotech strategies by several countries • 2001: Healthcare Spending by US Goverment passes 20% of governmental budget • 2001: Lisbon Agenda; Strategic vision of EU for Biotech in Europe • 11/2002: First People suffering from SARS identified in Province of Guangdong, China • 2005: 124 cases of bird flu reported, 63 persons death since 2003; 150 million animals killed for reasons of precaution
Web Resources:
• WHO